Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
14 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
The fund said its unaudited half-year results were for the six months ended 30 June 2026. Ordinary share NAV per share was US$2.393 at 30 June 2026, up 58% from US$1.510 at 31 December 2025.
The companies also agreed to a clinical trial collaboration to evaluate ivonescimab with sonesitatug vedotin in gastrointestinal cancers. Summit said AstraZeneca’s investment will be in convertible preferred shares.
Arvinas (NASDAQ: ARVN ) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. Access the full call at Summary Arvinas Inc. reported
For best results when printing this announcement, please click on link below: RNS Number: 1594W Clean Power Hydrogen PLC 24 September 2026 The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which is part of
For best results when printing this announcement, please click on link below: RNS Number: 0602W India Capital Growth Fund Limited 24 September 2026 INDIA CAPITAL GROWTH FUND LIMITED Interim Results for the six months ended 30 June 2026 24 September 2026, London - India Capital Growth Fund ("ICGF" or "the Company"), the
For best results when printing this announcement, please click on link below: RNS Number: 0622W BioPharma Credit PLC 24 September 2026 24 September 2026 BIOPHARMA CREDIT PLC ("BPCR" or "the Company") HALF YEAR REPORT FOR THE YEAR ENDED 30 JUNE 2026 BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt inv
The European Commission has granted marketing authorization for Menarini Group and NewAmsterdam Pharma's Ubeslo® (obicetrapib 10 mg monotherapy) and Evlarco® (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination) for patients with primary hypercholesterolaemia. This marks the first regulatory approval of obice
Braskem (NYSE: BAK ) released second-quarter financial results and hosted an earnings call on Friday. Read the complete transcript below. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. The full earnings call is available at Summary Braskem reported a
Gerdau (NYSE: GGB ) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. The full earnings call is available at Summary Gerdau reported a 7% increase in shipments
Fomento Economico (NYSE: FMX ) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. The full earnings call is available at Summary Fomento Economic
T-Mobile US (NASDAQ: TMUS ) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. View the webcast at Summary T-Mobile US reported strong Q2 2026 f
The companies said they have a binding letter agreement for strategic transactions around Blue Moon's Springer tungsten complex in Nevada. The package contemplates about $150 million of investment and standby requirements if needed to place the APT plant back in production.
FuelCell Energy said it secured its first order for FuelCell Energy Blocks for data center applications and lifted committed and awarded capacity backlog to $3.6 billion as of July 31.